ClinicalTrials.gg
RecruitingNCT05651932Updated Oct 22, 2026

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase 1 interventional study of Cohort A1 & A2: KTX-1001 and Cohort B1 & B2: KTX-1001+Mezigdomide in Multiple Myeloma, Myeloma and Myeloma Multiple, sponsored by K36 Therapeutics, Inc.. Recruiting at 29 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by K36 Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 8 months later.
Updated Oct 22, 2026Site recruiting status changed4 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
165
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Planned enrollment
53rd of 373
165 · median 45
Started
2023
with 14 others
Phase 1
42 of 381
5 open now
Primary completion
2027-12
later than 73 of 103 live
Registered
343rd of 381
by date

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 53rd largest by planned enrollment of the 373 interventional ones that give a count, is one of 15 that started in 2023, is one of 42 in phase 1, reaches primary completion later than 73 of the 103 other live ones, and was the 343rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Read the detailed description

This is a Phase I, open-label, dose-escalation and expansion study in adult patients with RRMM.

In the dose escalation phase (Part A), patients will be evaluated for DLTs during Cycle 1 (28 days). The KTX-1001 MTD, RP2D, and schedule will be determined.

In the dose expansion phase (Part B), patients with t(4;14) will receive KTX-1001 at the RP2D alone and in combination with investigational therapy Mezigdomide or SOC therapy (dexamethasone, carfilzomib or pomalidomide) to further define safety and tolerability and provide preliminary efficacy information.

03

Conditions studied

  • Multiple Myeloma
  • Myeloma
  • Myeloma Multiple

Keywords

  • NSD2
  • MMSET
  • WHSC1
  • T4;14
  • T(4;14)
  • translocation
  • myeloma
  • RRMM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria for Dose-Expansion:

  • ≥ 18 years of age
  • score ≤ 1
  • Multiple myeloma (as per IMWG)

    • Prior therapy for MM: Participants must have received at least 1 and up to 3 as defined by IMWG, and the following drug classes: PI, IMiD, and anti-CD38 antibody. For mezigdomide combination Cohorts B1 and B2, participants must have received at least 2 prior lines of therapy
    • Participants must have a confirmed diagnosis of progressive MM (per IMWG), t(4;14) confirmed by fluorescence in situ hybridization (FISH) testing performed in a centralized Clinical Laboratory Improvement Amendments (CLIA) accredited laboratory via fresh tumor .
  • , including at least 1 of the following criteria:

    • Serum M protein ≥ 0.50 g/dL (by SPEP)
    • Serum IgA ≥ 0.50 g/dL (IgA myeloma patients)
    • Urine M protein ≥ 200 mg/24 h (by UPEP)
    • sFLC involved light chain ≥ 10 mg/dL (100 mg/L) (patients with abnormal sFLC ratio)
    • Bone marrow plasma cells ≥ 30% (if only criterion for measurability)
  • Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)

Key Exclusion Criteria for Dose-Expansion:

  • Treatment with the following therapies in the specified time period prior to first dose:

    • Patients in Cohorts B1 and B2 must not have received prior mezigdomide treatment
    • Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2
    • Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D
    • Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks
    • Cellular therapies ≤ 8 weeks
    • transplant \< 100 days
    • Allogenic transplant ≤ 6 months, or > 6 months with active
    • Major surgery ≤ 4 weeks
  • Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis
  • Active CNS disease: participants with previously treated stable CNS disease are eligible, except for Cohorts B1 and B2 for which known CNS myeloma involvement is completely excluded.
  • Inadequate bone marrow function
  • Inadequate renal, hepatic, pulmonary, and cardiac function
  • Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.
  • Use of acid reducing agents and strong inhibitors or inducers of within 7 days or 5 half-lives (whichever is longer) prior to first dose
  • Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)
  • Active not related to myeloma requiring therapy within \< 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Cohort A (Single agent): KTX-1001 + dexamethasone

    Cohort A1 (single agent): KTX-1001 at RP2D1 + dex Cohort A2 (single agent): KTX-1001 at RP2D2 + dex

    Drug: Cohort A1 & A2: KTX-1001

  • Experimental
    Cohort B (Mezigdomide): KTX-1001 + Mezigdomide + dex

    Cohort B1 (Mezigdomide): KTX-1001 at RP2D1 + Mezigdomide + dex Cohort B2 (Mezigdomide):: KTX-1001 at RP2D2 + Mezigdomide + dex

    Drug: Cohort B1 & B2: KTX-1001+Mezigdomide

  • Experimental
    Cohort C (carfilzomib/KYPROLIS®): KTX-1001 + carfilzomib + dex

    Cohort C1 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D1 + carfilzomib + dex Cohort C2 (carfilzomib/KYPROLIS®): KTX-1001 at RP2D2 + carfilzomib + dex

    Drug: Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)

  • Experimental
    Cohort D (pomalidomide): KTX-1001 + pomalidomide + dex

    Cohort D (pomalidomide): KTX-1001 at RP2D2 + pomalidomide + dex

    Drug: Cohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)

Interventions

  • KTX-1001: Orally for 28 days each cycle until progression. Dexamethasone: Orally once weekly

    Also known as: KTX-1001, Dexamethasone

  • DrugCohort B1 & B2: KTX-1001+Mezigdomide

    Drug page: Mezigdomide

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Mezigdomide Dexamethasone: Orally once weekly

    Also known as: Mezigdomide

  • DrugCohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)

    Drug page: Carfilzomib

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once weekly Drug: Carfilzomib (KYPROLIS®): IV, once weekly for 3 weeks in each 28-day cycle

    Also known as: Carfilzomib (KYPROLIS®), Dexamethasone

  • DrugCohort D: KTX-1001+ pomalidomide (Pomalyst, Imnovid)

    Drug page: Pomalidomide

    Drug: KTX-1001: Orally for 28 days each cycle until progression Drug: Dexamethasone: Orally once a week Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle

    Also known as: Pomalidomide (Pomalyst, Imnovid), Dexamethasone

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Determination of Recommended Phase 2 Dose (RP2D) and/or Maximum Tolerated Dose (MTD) Dose Expansion: Provide preliminary efficacy data on the antitumor effects of KTX-1001 in combination with other anti-myeloma therapy

    Incidence of dose-limiting toxicity (DLTs), treatment-emergent adverse events (TEAEs), treatment-related AEs, and clinically significant changes in laboratory test results

    Time frame: Cycle 1 (28 days)

Secondary outcomes

  1. Disease Specific Response to KTX-1001± Combination Therapy

    Objective Response Rate (ORR) Duration of Response (DOR) Progression Free Survival (PFS) Minimal Residual Disease (MRD) Per IMWG Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma

    Time frame: Duration of Study

  2. Pharmacokinetics & Pharmacodynamics KTX-1001± Combination Therapy

    Maximum plasma concentration (Cmax) of KTX-1001 Time to achieve Cmax (tmax) for KTX-1001 Area under the plasma concentration-time curve (AUC) for KTX-1001

    Time frame: Duration of Study

  3. Safety profile of KTX-1001± Combination Therapy

    Frequency and severity of TEAEs, treatment-related AEs, and clinically significant changes in laboratory test results

    Time frame: Duration of Study

07

Study locations

26 of 29 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 58 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 15, 2022
StartActual
Feb 22, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 1 site removed. Cleveland Clinic - Taussig Cancer Institute is now Recruiting
Show 4 added (3 United States, 1 Canada)
  • University of Michigan · Ann Arbor, United States
  • Oncology Consultants · Houston, United States
  • Northwest Medical Specialties, PLLC · Tacoma, United States
  • Cross Cancer Institute · Edmonton, Canada
Show 1 removed
  • Northwest Medical Specialties · Tacoma, United States
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    4 sites added, 1 site removed. Cleveland Clinic - Taussig Cancer Institute is now Recruiting
    Show 4 added (3 United States, 1 Canada)
    • University of Michigan · Ann Arbor, United States
    • Oncology Consultants · Houston, United States
    • Northwest Medical Specialties, PLLC · Tacoma, United States
    • Cross Cancer Institute · Edmonton, Canada
    Show 1 removed
    • Northwest Medical Specialties · Tacoma, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05651932
Lead sponsor
K36 Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Feb 22, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Soo Bang, MHSA
Contact
sbang@k36tx.com
1-347-342-7199
Latasha Nisbett, MS
Contact
lnisbett@k36tx.com
1-617-347-5787

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Mezigdomide · Carfilzomib · Pomalidomide

Start the discussion